76 results on '"Sherr, Jennifer L."'
Search Results
2. Real-World Evidence of Omnipod® 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes
3. Severe Hypoglycemia and Impaired Awareness of Hypoglycemia Persist in People With Type 1 Diabetes Despite Use of Diabetes Technology: Results From a Cross-Sectional Survey
4. Postprandial Glucose Variability Following Typical Meals in Youth Living with Type 1 Diabetes
5. A narrative commentary about interoperability in medical devices and data used in diabetes therapy from an academic EU/UK/US perspective
6. The Acute Effects of Real-World Physical Activity on Glycemia in Adolescents With Type 1 Diabetes: The Type 1 Diabetes Exercise Initiative Pediatric (T1DEXIP) Study
7. Two Years with a Tubeless AID System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes
8. Safety and glycemic outcomes during the MiniMed™ advanced hybrid closed-loop (AHCL) system pivotal trial in children and adolescents with type 1 diabetes
9. Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine
10. Contributors
11. The dawn of automated insulin delivery: from promise to product
12. OGTT Metrics Surpass Continuous Glucose Monitoring Data for T1D Prediction in Multiple-Autoantibody–Positive Individuals
13. Answering clinically pertinent questions with real-world data from paediatric type 1 diabetes registries
14. Impact of School‐supervised Ultra‐long‐acting Basal Insulin Injections on Ketosis in Youth with T1D and Elevated Hemoglobin A1c: A Pilot Study
15. Update on Measuring Ketones
16. CGM Metrics Identify Dysglycemic States in Subjects from the TrialNet Pathway to Prevention Study
17. CGM Metrics Identify Dysglycemic States in Subjects from the TrialNet Pathway to Prevention Study
18. Diabetes Technology Meeting 2022
19. ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery
20. Automated Insulin Delivery: Benefits, Challenges, and Recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association
21. Automated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association
22. Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice
23. Future Drug Treatments for Type 1 Diabetes
24. How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: Findings from the first investigation with the Omnipod® 5 System
25. Safety and Glycemic Outcomes with a Tubeless Automated Insulin Delivery System in Very Young Children with Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial
26. Safety and Glycemic Outcomes with a Tubeless Automated Insulin Delivery System in Very Young Children with Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial
27. Diabetes Technology Meeting 2021
28. Clinical Implementation of the Omnipod 5 Automated Insulin Delivery System: Key Considerations for Training and Onboarding People With Diabetes
29. A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings
30. Continuous Ketone Monitoring Consensus Report 2021
31. Hemoglobin A1c Patterns of Youth With Type 1 Diabetes 10 Years Post Diagnosis From 3 Continents
32. Type 1 diabetes glycemic management: Insulin therapy, glucose monitoring, and automation
33. Diabetes Technology Meeting 2020
34. Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes
35. Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes
36. Safety Evaluation of the Omnipod® 5 Automated Insulin Delivery System Over Three Months of Use in Adults and Adolescents With Type 1 Diabetes (T1D)
37. Safety Evaluation of the Omnipod® 5 Automated Insulin Delivery System Over Three Months of Use in Children With Type 1 Diabetes (T1D)
38. Incident diabetes complications among women with type 1 diabetes based on parity
39. Changes in Device Uptake and Glycemic Control Among Pregnant Women With Type 1 Diabetes: Data From the T1D Exchange
40. High residual C-peptide likely contributes to glycemic control in type 1 diabetes
41. Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions
42. Effect of Exercise and Meals on Continuous Glucose Monitor Data in Healthy Individuals Without Diabetes
43. A Technological Revolution: The Integration of New Treatments to Manage Type 1 Diabetes
44. Pharmacologic treatment options for type 1 diabetes: what’s new?
45. Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy
46. Connecting the Dots: Validation of Time in Range Metrics With Microvascular Outcomes
47. Gender differences in diabetes self-care in adults with type 1 diabetes: Findings from the T1D Exchange clinic registry
48. Enlarging the loop: closed-loop insulin delivery for type 1 diabetes
49. ISPAD Clinical Practice Consensus Guidelines 2018: Diabetes technologies
50. Accuracy of a Fourth-Generation Continuous Glucose Monitoring System in Children and Adolescents with Type 1 Diabetes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.